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Abstract 
Pathological changes in an organ or tissue may be reflected in proteomic 
patterns in serum. The early detection of cancer is crucial for successful 
treatment. Some cancers affect the concentration of certain molecules in the 
blood, which allows early diagnosis by analyzing the blood mass spectrum. It is 
possible that exclusive serum proteomic patterns could be used to differentiate 
cancer samples from non-cancer ones. Several techniques have been 
developed for the analysis of mass-spectrum curve, and use them for the 
detection of prostate, ovarian, breast, bladder, pancreatic, kidney, liver, and 
colon cancers. In present study, we applied data mining to the diagnosis of 
ovarian cancer and identified the most informative points of the mass-spectrum 
curve, then used student t-test and neural networks to determine the differences 
between the curves of cancer patients and healthy people. Two serum SELDI 
MS data sets were used in this research to identify serum proteomic patterns 
that distinguish the serum of ovarian cancer cases from non-cancer controls. 
Statistical testing and genetic algorithm-based methods are used for feature 
selection respectively. The results showed that (1) data mining techniques can 
be successfully applied to ovarian cancer detection with a reasonably high 
performance; (2) the discriminatory features (proteomic patterns) can be very 
different from one selection method to another.  
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Introduction 
Ovarian carcinoma has the highest mortality rate and form the leading cause of death from 
gynaecologic malignancy, which is due to its late initial diagnosis in addition to recurrence 
of ovarian cancer associated with resistance to therapy [1–3] resulting in approximately 
21,880 estimated new cases in 2010 with an estimated 13,850 deaths in 2010 in the USA 
[4]. Among ovarian malignancies, approximately 90% epithelial ovarian cancer is arising 
from the ovarian surface epithelium (OSE) [5]. Because of late diagnosis, less than 20% of 
stage IV and less than 40% of stage III patients with ovarian cancer survive for 5 years [6]. 
The failure of early diagnosis includes mistaking symptoms for a gastrointestinal disease 
and unavailability of adequate sensitive screening and detection methods for precise 
detection of ovarian cancer in its primitive stage. 
A conventional methodology for early stage detection of ovarian cancer includes 
application of biomarkers like CA125, but this strategy is restricted by its high cost and 
labour intensity [7]. Another approach, cDNA microarrays, has also been used to 
recognize unregulated genes in cancer tissue, using prostasin, osteopontin, and He4 
markers [8–10]. A limitation of the cDNA microarray approach is that transcriptional 
differences in the tumor do not completely emulate the protein observed peripherally, 
because change in protein patterns found in blood is due to protein–protein interactions 
and post-translational modifications. 
Recently, a protein chip tied with Surface Enhanced Laser Desorption/Ionization Time-Of-
Flight Mass Spectrometry (SELDI-TOF MS) has been developed to assist protein profiling 
of complex biological mixtures, with high efficacy of discovering the cancer protein markers 
in serum or plasma [11].  
Combinations of SELDI-TOF MS with bioinformatics approach successfully establish some 
new biomarkers and achieved high sensitivity and specificity for ovarian cancer diagnosis 
[11–13]. Recently the application of feature extraction techniques to proteomic data is 
widely used for cancer detection. [14–17]. Sorace and Zhan [18] used mass spectrometry 
serum profiles to detect early ovarian cancer while Petricoin et al. [11] applied genetic 
algorithm in combination with self-organizing cluster analysis for identifying ovarian cancer 
and reported a discriminatory pattern for ovarian cancer, which was defined by the 
amplitudes at 5 key M/Z values. This technique gave a sensitivity of 100% and a specificity 
of 95%.  
The mass spectrum data present a curve with peaks and valleys, where the x-coordinate 
is the ratio of molecular weight to the net electrical charge for a specific organic molecule, 
with Dalton (Da) as unit, and biomarker identification. Although proteomic mass spectra 
has shown the promising potential of finding disease-related protein patterns but still some 
challenges remained unsolved.  
The objective of this study is to determine whether SELDI-TOF MS profiling of plasma 
proteins coupled with an artificial intelligence data analysis algorithm could efficiently 
distinguish between normal controls and patients with malignant ovarian cancer. Using a 
standardized training set, we demonstrated that our SELDI protein profiling approach 
could accurately distinguish between plasma from patients with ovarian cancer and that 
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In the present study, an alternative approach of feature selection from mass spectroscopy 
data of ovarian cancer is proposed. This article introduces the method of serum protein 
analysis based on feature selection using student t-test and classification with neural 
networks, establishing a new pattern for diagnosis of ovarian cancer. 
Results and Discussion 
Ovarian cancer lacks any apparent early detection or screening test, which means that 
most cases remain undiagnosed until they have reached advanced stages. About 90% of 
patients are diagnosed at stage III or stage IV cancer, when it has already spread beyond 
the ovaries and for these patients 5 year survival rates are less than 30%. However, the 
small percentage of patients diagnosed with stage I ovarian cancer confined to the ovaries 
have a 5 year survival rate in excess of 90%.  
The exact cause of ovarian cancer is unknown, which hampers  the focus on early 
detection of ovarian cancer. The connection between diagnosis and survival in ovarian 
cancer has provided a rationale for efforts to improve results obtained by early stage 
detection. However, it is not confirmed whether the currently available screening methods 
can detect ovarian cancer sufficiently early to permit interference to change the normal 
record of the disease. There are no standard recommendations for screening for ovarian 
cancer. Screening women with pelvic ultrasound or blood tests, such as the evaluation of 
the tumor marker CA 125  has not been found to be very effective and is not recom-
mended.  
Ovarian cancer detection 
In present work pre-processing of mass spectra is done by selecting the most significant 
features that confine the majority of the biological information unseen in the original noisy 
spectra using student t-test and at last performing high-accuracy classification using feed 
forward neural network to spectra (Scheme 1). A special class of ANN i.e. Multi layer 
Perception (MLP) is applied. In MLP, the neurons are structured into layers and there are 
no lateral connections between neurons in the same layer and no feedback connections to 
neurons in previous layers. Thus, such networks are also named as Feed-Forward 
Artificial Neural Networks (FFANNs). In MLP, the biased sum of the inputs and bias terms 
are passed to activation level through a transfer function to produce the output, and the 
units are arranged in a layered feed-forward topology. The hidden layer enormously 
increases the learning power of the MLP. For MLP network architecture, a single hidden 
layer with sigmoid activation function, which is optimal for the dichotomous outcome, is 
chosen.  The transfer function is selected such that the algorithm requires a response 
function with a continuous, single-valued with first derivative existence.  Further, the 
transfer or activation function of the network modifies the input to give a required output. 496  A. Thakur, V. Mishra, and S. K. Jain:   
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Sch. 1.   Algorithmic approach used in present study 
Comparison of mass spectra from two initial datasets which include 95 controls (green) 
and 121 ovarian cancer patients (blue) is made (Fig. 1a). The small subset (5 from both) 
along the spectrum x-axis is identified and evaluated as significant because the prototype 
of amplitudes at these M/Z values entirely split out the serum of ovarian cancer patients 
from the controls. The finest discriminatory pattern in N-space for ovarian cancer is given 
by the amplitudes at the input M/Z values between 8450–8740 which can be visualized in 
the magnified view of the spectrum (Fig. 1b). However, the plot of the group average and 
the envelopes of each group show no significant feature for absolute discrimination 
between ovarian cancer patient and controls (Fig.  2). Therefore, to determine class 
discrimination, we implemented ranking the features approach using student t-test. Fig. 3 
represents the plot of ranked features. It can be observed that there are significant regions 
at high M/Z values but have low intensity (~8150 Da). This peak is visibly clear from the 
background noise. 
Input serum MS spectra data 
Ovarian cancer patient (216)  Healthy control (95) 
Creation of multiple sample spectrograms (M/Z vs ion intensity) 
Feature selection using student t-distribution method 
Designing, training and testing of neural network classifier 
Overall performance of proposed method 
Specificity  Sensitivity  Accuracy 
Output 
Control  Cancer   Feed Forward Artificial Neural Network: Tool for Early Detection of Ovarian Cancer  497 





Fig. 1.   a: This study uses the high-resolution Ovarian Cancer data set that was 
generated using the WCX2 protein array. The sample set includes 121 cancer, 
95 normal state. Plot of some data sets into a Figure window to visually 
compare profiles from the groups; in these graph 5 spectrograms from Ovarian 
Cancer patients (blue) and 5 from control patients (green). 
b: Zooming in on the region from 8450 to 8700 M/Z shows some peaks that 
might be useful for classifying the data. 498  A. Thakur, V. Mishra, and S. K. Jain:   
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Fig. 2.   Plot of the group average and the envelopes of each group. Observe that 
apparently there is no single feature that can discriminate both groups perfectly. 
 
Fig. 3.   Plot of ranked features. Note that there are significant regions at high M/Z 
values but low intensity (~8150 Da). The approaches to measure class 
separability are performed using in ranking features, such as student t-test.   Feed Forward Artificial Neural Network: Tool for Early Detection of Ovarian Cancer  499 
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Overall performance of proposed method 
The results for estimated testing accuracy and training accuracy of this classifier have 
been shown in Table 1.  This end result gave 100% training accuracy in active and 
controlled state ovarian cancer patient with 99.16% and 98.50% testing accuracy in active 
and controlled state ovarian cancer patient respectively. Training, eliminate inappropriate 
and/or redundant data points (features) from the data (feature) set, and discovers the 
smallest size subset of data points as features that holds sufficient information to execute 
a well-organized pattern of classification.  
Tab. 1.   The Overall performance of the proposed method 
Type of Data  Number of 
Dataset used 
for Training 





% Testing  
Accuracy 
Active Ovarian Cancer  100  11  100  99.16 
Controlled Ovarian Cancer  80  95  100  98.50 
 
Comparison with the Linear Discriminant Analysis (LDA) classifier method 
Linear Discriminant Analysis (LDA) is a non-parametric method [19] that is also a special 
form of a maximum probability discriminant rule for multivariate normal class densities with 
the same covariance matrix. In LDA method the number of features that can be handled 
has to be smaller than the number of observations. For that reason, we cannot use all the 
intensity values from an MS data set for these classification methods. As an alternative, 
we have to recognize certain M/Z ratios as inputs to these methods, and it is obvious that 
this feature selection step is crucial in the analysis of MS data and comparison of various 
methods. To construct the evaluation as suitable as possible, we feed the similar set of 
M/Z ratios to LDA classification method and compare its performance on our data. It is 
important to note that the intensities of the selected M/Z features are of particularly small 
amplitude, indicating at finest only 2% of the intensity of the most abundant peaks present 
in the serum mass spectra.  
In present study we have also compared results acquired with LDA classification method 
to distinguish ovarian cancer patients from normal individuals based on MS data obtained 
by serum samples. Table 2 shows the result for the integrated feed forward ANNs 
classifier, the estimated overall sensitivity was found to be 98% and the estimated positive 
predictive value was found to be 96%. The same data were used by linear discriminant 
analysis, in original grouped data; the estimated overall sensitivity was found to be 85%, 
and the estimated specificity was 71%. 
Tab. 2.  The comparison with the LDA classifier method 
Classifier  Overall Sensitivity  Specificity 
LDA  85%  71% 
Feed Forward ANN  98%  96% 
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On comparison to LDA methods, our method has the benefit of not involving the number of 
variables used to be less than the number of subjects in the study, which is an obvious 
advantage for the study of MS data as the number of M/Z versus intensity data points is 
very large. The result of major discrimination among cancer and control groups at high M/Z 
values signifies that concentration should be focused in this particular region (8450–8740) 
only (Fig.  1a and 1b, 2). Particularly, after excluding the uncertain section and noise 
effects this region can be establish to propose the best for ovarian cancer diagnostic test 
development. The whole data set can be visualized by looking at average signal for the 
control and cancer samples which can be observed by the plot of the group average and 
the envelopes of each group (Fig. 2). Significant features can be determined by assuming 
that each M/Z ratio is independent. Rank features return an index to the most significant 
M/Z values, by the absolute value of the test statistic. Comparisons (t-testing) revealed 
that the variation in the mass spectra between ovarian cancer patient and controls was 
statistically distinguishable from the variance within the method itself, as indicated by plot 
of ranked features (Fig. 3).  
In this paper, we presented a learning method to examine ovarian cancer proteomics data 
that utilized ANN as a classifier and feature selection scheme in a cross validation 
framework.  The accuracy of tools depend on several factors such as size, quality of 
training set, and also the parameters chosen to represent input. In this preliminary 
evaluation, only two data sets from ovarian cancer database are used. The chosen feature 
sets combined with the neural network can provide a good solution for automatic ovarian 
cancer diagnosis system in the future.  
Experimental  
Materials 
Present research is based on the serum proteomic analysis of the input Serum SELDI 
spectra data from patients with ovarian cancer and a healthy screening population. Serum 
MS data set is used to recognize serum proteomic patterns to discriminate the serum of 
ovarian cancer patients from healthy controls. The dataset was downloaded from the FDA-
NCI Clinical Proteomics Program Databank [20]. This study uses the high-resolution 
ovarian cancer data set generated by WCX2 protein array. The sample set includes 95 
controls and 121 ovarian cancer.  
Methods 
Feature Selection 
For the feature selection, every point of mass spectrum curve was observed as a feature 
and the equivalent ion intensity as its value. The significant features were selected by the 
calculation of mean intensity values for every point in mass spectra of cancer and control 
groups. Student t-test was employed as a method to separate both the groups. Two-
sample student t test considered each feature independently. It was assumed that both 
groups of data values were distributed normally and had similar variances. Test statistics 
were calculated as follow:   Feed Forward Artificial Neural Network: Tool for Early Detection of Ovarian Cancer  501 









Where, Xd and Xc – mean values of intensities from disease and control group.  
Vard and Varc – variances of two distributions.  
nd and nc – numbers of instance in each distribution.  
This t value followed student t distribution with (nd + nc − 2) degree of freedom. On the 
basis of test statistics and t distribution, the significance p value was calculated. The main 
features for classification are shown in Fig. 3. 
Artificial Neural Network  
Artificial Neural Networks (ANNs) are computer-based algorithms that are modelled on the 
organization and performance of neurons in the human brain and can be trained to identify 
and classify complex patterns. Pattern recognition is accomplished by regulating 
parameters of the ANN by a method of error reduction through learning from training. It 
can be standardized by applying any kind of input data, such as proteomics data 
generated by SELDI-TOF MS, and the output can be grouped into any given number of 
categories. 
In present work, neural network classifier was designed, trained and tested using the 
feature sets described above. In training, data from different files of ovarian cancer mass-
spectrometry database were selected as representatives of various classes. The classifier 
was tested over a large set of database for robustness. This segment describes the 
methods used in design, training, and testing the neural network classifier. 
Design 
A Feed-Forward Multi-Layer Perception (FFMLP) neural network with a single hidden layer 
is implemented for classification [21]. It is the most widely used neural network method for 
pattern recognition [22, 23]. Multi-Layer Perception is composed of three layers i.e. an 
input layer, an output layer, and one or more hidden layers, that take out useful information 
during learning and give modifiable weighting coefficients to components of the input 
layers.  We explored various other implementations empirically selected this particular 
network since it achieved the best performances. The number of neurons in the hidden 
layer was set equal to five neurons. All computations were performed in Matlab® version 
R2008a (The Mathworks, Natick, MA, USA). 
Training and Testing 
During training, MLPs fabricate a multidimensional space, defined by the start of the 
hidden nodes, so that patients as well as controls are as distinguishable as possible. In the 
present study, total 216 files of ovarian cancer were taken which formed 1 Test set and 
include 173 (which is 80% of total files taken) training subset and 43 (20%) test subset. 
These files are selected as representatives of Active and Controlled state. The selected 
two classes are categorised using one against all.  502  A. Thakur, V. Mishra, and S. K. Jain:   
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Classifier Performance Measures 
We quantified our classifier performance using the most common metrics found in 
literature: accuracy, sensitivity, and Specificity.  
Accuracy: 
It is the most crucial metric for determining overall system performance and is the test’s 
total accurate diagnosis of the sick and the healthy.  The overall accuracy (A) of the 
classifier for each file is as follows [22]: 




The variables Ne and Nb represent the total number of classification errors and beats in the 
file, respectively. 
Sensitivity: 
It is the ability to distinguish the sick from the true ill [24]. It measures how effectively a 





Where  Tp,  Fp, and FN  denote true positives, false positives and false negatives 
respectively. 
Specificity: 
It is the probability that a person who does not have a disease will be correctly identified by 
a clinical test. Specificity measures how exclusively it classifies beats of a certain type. 
True positives are proteomic data segment which have been precisely assigned to a 
certain class whereas false positives are data which have been incorrectly assigned to that 
same class. False negative is denoted as a result that appears negative but fails to reveal 
a situation. A test result that shows no evidence of the disease or abnormality being 
investigated although the condition is actually present. 
Analytical Procedure 
The serum mass spectrum data is used as an input for analysis. Each mass spectrum data 
is composed of 12,000 M/Z values on the x-axis with corresponding intensities of ovarian 
cancer patients and controls  on the y axis. The output of the algorithm is the robust 
separation of amplitudes at defined M/Z values that finest isolates the initial data. 
The t-statistics is applied to pre-select a set of variables as inputs for classifiers for which 
variables are ranked, i.e. M/Z ratios, based on normalized difference between two groups 
(cancer and control groups), and then the variables are chosen on the basis of the 
absolute values of t-statistics. 
All candidate subset includes 5 of the 12000 potential x-axis values that depict the spectra 
and the robustness of the test consists of plotting the pattern generated by the collective y-
axis amplitudes of the candidate set of key M/Z values in N-dimensional space, where N is   Feed Forward Artificial Neural Network: Tool for Early Detection of Ovarian Cancer  503 
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the number of M/Z values in the test set. The pattern produced by the virtual amplitude of 
the spectrum data for this set of selected values is charged for its capability to differentiate 
the two preliminary populations. The M/Z  values within the highest rated sets are 
reshuffled to form new subset candidates and the resultant y-axis-defined amplitudes are 
rated iteratively until the set that fully discriminates the preliminary set emerges. All 
computations used in this study are performed in Matlab® version R2008a (The 
Mathworks, Natick, MA, USA). 
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